What's in a Name? Why Words Matter in Advanced Prostate Cancer

William K Oh¹, Neeraj Agarwal², Alan Bryce³, Pedro Barata⁴, Courtney Bugler⁵, Sigrid V Carlsson⁶, Brad Cornell⁷, William Dahut⁸, Daniel George⁹, Stacy Loeb¹⁰, Bruce Montgomery¹¹, David Morris¹², Lorelei A Mucci¹³, Aurelius Omlin¹⁴, Ganesh Palapattu¹⁵, Irbaz Bin Riaz¹⁶, Charles Ryan¹⁷, Martin W Schoen¹⁸, Samuel L Washington 3rd¹⁹, Silke Gillessen²⁰

Affiliations

¹ Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: william.oh@mssm.edu.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.
³ Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, AZ, USA.
⁴ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁵ Zero Prostate Cancer, Washington, DC, USA.
⁶ Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden.
⁷ Patient advocate.
⁸ American Cancer Society, Atlanta, GA, USA.
⁹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
¹⁰ Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY, USA.
¹¹ Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹² Urology Associates PC, Nashville, TN, USA.
¹³ American Cancer Society, Atlanta, GA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
¹⁴ Onkozentrum Zürich und Uroonkologisches Zentrum, Hirslanden Zürich, Zurich, Switzerland.
¹⁵ Department of Urology, University of Michigan, Ann Arbor, MI, USA.
¹⁶ Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.
¹⁷ Zero Prostate Cancer, Washington, DC, USA / University of Minnesota, Minneapolis, MN, USA.
¹⁸ Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO, USA.
¹⁹ Department of Urology, University of California-San Francisco, San Francisco, CA, USA.
²⁰ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

PMID: 39472202
DOI: 10.1016/j.eururo.2024.10.017

Editorial

What's in a Name? Why Words Matter in Advanced Prostate Cancer

William K Oh et al. Eur Urol. 2025 Feb.

. 2025 Feb;87(2):101-103.

doi: 10.1016/j.eururo.2024.10.017. Epub 2024 Oct 29.

Authors

Affiliations

¹ Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: william.oh@mssm.edu.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.
³ Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, AZ, USA.
⁴ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁵ Zero Prostate Cancer, Washington, DC, USA.
⁶ Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden.
⁷ Patient advocate.
⁸ American Cancer Society, Atlanta, GA, USA.
⁹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
¹⁰ Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY, USA.
¹¹ Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹² Urology Associates PC, Nashville, TN, USA.
¹³ American Cancer Society, Atlanta, GA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
¹⁴ Onkozentrum Zürich und Uroonkologisches Zentrum, Hirslanden Zürich, Zurich, Switzerland.
¹⁵ Department of Urology, University of Michigan, Ann Arbor, MI, USA.
¹⁶ Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.
¹⁷ Zero Prostate Cancer, Washington, DC, USA / University of Minnesota, Minneapolis, MN, USA.
¹⁸ Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO, USA.
¹⁹ Department of Urology, University of California-San Francisco, San Francisco, CA, USA.
²⁰ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

PMID: 39472202
DOI: 10.1016/j.eururo.2024.10.017

Abstract

Much of the disease nomenclature used for patients with advanced prostate cancer has negative connotations and can be confusing or intimidating. Experts in the field convened to recommend a clearer and more accurate approach to defining the nomenclature.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

What's in a Name? Why Words Matter in Advanced Prostate Cancer

Affiliations

What's in a Name? Why Words Matter in Advanced Prostate Cancer

Authors

Affiliations

Abstract

Publication types

MeSH terms